Can Chronic Post-surgical Pain be Reduced by Preserving Intercostobrachial Nerve During Axillary Lymph Node Dissection? : A Randomized Controlled Trial

Not Applicable

• Conditions: Breast Cancer; Chronic Pain; Intercostobrachial Nerve Injury
• Interventions: Procedure: Intercostobrachial Nerve Preserving Axillary Lymph Node Dissection; Procedure: Intercostobrachial Nerve Sacrificing Axillary Lymph Node Dissection

• Registration Number: NCT05198622
• Lead Sponsor: Shaukat Khanum Memorial Cancer Hospital & Research Centre

Brief Summary

Intercostobrachial nerve (ICBN) is a cutaneous nerve that provides sensation to the lateral chest, upper medial arm and axilla. It arises from the second intercostal nerve and leave intercostal space at the level of midaxillary line. It then pierces the serratus anterior muscle and enters axilla. Intercostobrachial nerve is encountered during axillary lymph node dissection (ALND) while mobilizing axillary contents laterally off the chest wall and tends to tether axillary contents to the lateral chest wall. Many surgeons routinely sacrifice it as doing so makes mobilization easier and allow exposure of long thoracic neve. Currently there is no consensus on the usefulness of preserving intercostobrachial nerve.

According to a 2020 systemic review and meta-analysis, prevalence of CPSP/ PPSP following breast cancer surgery ranged from 2% to 78% and pooled prevalence was found to be 35%. Higher prevalence was associated with ALND. Several risk factors have been identified which contribute to the development of PPSP. These include; Preexisting pain, preoperative opioid exposure, genetics, psychological factors such as anxiety, depression or catastrophizing, intensity of acute postoperative pain and nerve injury during surgery.

As a result of nerve injury, damaged and non-damaged nerve fibers start generating action potential spontaneously. These are considered ectopic inputs as they do not arise from peripheral terminals. These inputs lead to the development of central sensitization, which is a state of exaggerated functional response of neurons involved in the pain pathway. This increased sensitization results due to increased membrane excitability, enhanced synaptic efficacy and decreased inhibition.

The aim of the present trial is to investigate the effect of ICBN preservation on chronic/ persistent post surgical pain (CPSP/ PPSP). This will be achieved through a randomized control trial with CPSP/ PPSP as a primary outcome measure. Secondary outcome measures will include Health Related Quality of Life (HRQoL), operating time, lymph node yield, functional status of ipsilateral shoulder, post-operative complications and post-operative use of opioid analgesics.

Detailed Description

Not available

Study Timeline

• Status Verified: 2022-01
• Study First Submitted: 2022-01-09
• Study First Submitted QC: 2022-01-18
• Study First Posted: 2022-01-20
• Study Start: 2022-01-30
• Last Update Submitted: 2022-01-30
• Last Update Posted: 2022-02-01
• Primary Completion: 2022-10-01
• Study Completion: 2022-10-01

Recruitment & Eligibility

• Status: UNKNOWN
• Sex: Female
• Target Recruitment: 182

Inclusion Criteria

• Aged 18 or above.
• Known cases of invasive breast Cancer.
• Undergoing Axillary Lymph Node Dissection (ALND) alone, ALND with mastectomy or ALND with breast conservation surgery (BCS)
• Capacity to give informed consent

Exclusion Criteria

• Chronic diseases limiting motion of shoulder such as neuropathies, history of trauma and autoimmune diseases.
• Patients undergoing redo axillary lymph node dissection.
• Patients undergoing bilateral axillary lymph node dissection.
• History of chronic pain lasting more than 3 months. Potential causes include: arthritis, backache, fibromyalgia, Irritable bowel disease, irritable bowel syndrome and different types of headache.
• M1 stage of the TNM staging system at the time of initial diagnosis.

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
Intercostobrachial Nerve Preservation Arm	Intercostobrachial Nerve Preserving Axillary Lymph Node Dissection	Intercostobrachial nerve preserving axillary lymph node dissection will be carried out. Post-operatively, the patients will be monitored in the post anesthesia care unit (PACU). Acute Post-Operative pain will be controlled using a standardized pain management regimen in accordance with World Health Organization (WHO) analgesia ladder. The patients will be discharged from PACU and admitted to surgical ward once numerical rating score (NRI) is below 4.
Intercostobracial Nerve Sacrifice Arm	Intercostobrachial Nerve Sacrificing Axillary Lymph Node Dissection	Intercostobrachial nerve sacrificing axillary lymph node dissection will be carried out. Post-operatively, the patients will be monitored in the post anesthesia care unit (PACU). Acute Post-Operative pain will be controlled using a standardized pain management regimen in accordance with World Health Organization (WHO) analgesia ladder. The patients will be discharged from PACU and admitted to surgical ward once numerical rating score (NRI) is below 4.

Primary Outcome Measures

Name	Time	Method
Persistent Post-Surgical Pain (PPSP) using Brief Pain Inventory-Short Form (BPI SF)	6 Months (Post-Operatively)	BPI SF is a validated tool for the measurement of chronic pain. It assesses average pain intensity over the past 24 hour period. It defines pain as follows: Mild Pain: Score 1-4 Moderate Pain: Score 5-6 Severe Pain: Score 7-10 Recall Period: Last 24 hours

Secondary Outcome Measures

Name	Time	Method
Operating Time (Minutes)	Intraoperative	Operating Time is the time duration from incision to the closure. It will be measured in minutes.
Lymph Node Yield	Intraoperative	Lymph node yield is the total number of benign or malignant lymph nodes found in the axillary lymph node dissection specimen at the time of histopathological analysis.
Post-Operative usage of Opioid Analgesics	2 weeks (Post-Operatively), 3 months (Post-Operatively) and 6 months (Post-Operatively)	Type of opioid analgesic and prescribed daily dose in the post-operative period
Functional Status of Ipsilateral Shoulder using Shoulder Pain and Disability Index (SPADI) Questionnaire	Baseline (Pre-Operatively), 2 weeks (Post-Operatively), 3 months (Post-Operatively) and 6 months (Post-Operatively)	SPADI is a validated tool for the measurement of shoulder pain and disability. It is composed of pain component and functional assessment component. Each item in score component is rated from 0 (no pain) to 10 (worst imaginable pain) whereas items in functional assessment component are rated from 0 (no difficulty) to 10 (so difficult it requires help). The total score is expressed as a percentage. A higher score indicates more disability.; Recall Period: Last 7 Days
Post-Operative Complications as per Clavien Dindo Classification (CDC)	From the time of intervention to 30 days (Post-Operatively)	Clavien Dindo Classification divides the severity of post-operative complications based on the level of medical intervention needed. CDC is as following: Grade I: Any deviation from the normal postoperative course without the need for pharmacological treatment or surgical, endoscopic and radiological interventions. Allowed therapeutic regimens are: drugs as antiemetics, antipyretics, analgesics, diuretics, electrolytes and physiotherapy. This Grade also includes wound infections opened at the bedside.; Grade II: Requiring pharmacological treatment with drugs other than such allowed for Grade I complications. Blood transfusions and total parenteral nutrition are also included.; Grade III (a): intervention not under general anesthesia Grade III (b): intervention under general anesthesia Grade IV: Life-threatening complication (including complications of the Central Nervous System) requiring Intermediate Care/Intensive Care Unit management Grade V: Death of a patient
Health Related Quality of Life using Functional Assessment of cancer therapy-Breast form (FACT-B)	Baseline (Pre-Operatively), 2 weeks (Post-Operatively), 3 months (Post-Operatively) and 6 months (Post-Operatively)	FACT-B is a 37 item, validated tool for the measurement of health of health related quality of life (HRQoL). It consists of five subscales: Physical well being, emotional well being, social well being, functional well being and a breast cancer-specific subscale. Items are rated from 0 (not at all) to 4 (very much) and a total score is calculated. The total score ranges from 0-148. Lower score indicates a better health related quality of life.; Recall Period: Last 7 Days
Adverse Events	From the time of intervention to 6 months (Post-Operatively)	All adverse events will be documented on case report forms. The data management committee (DMC) will review these adverse events and determine if these are due to the intervention.

Trial Locations

Locations (1)

Shaukat Khanum Memorial Cancer Hospital & Research Centre; 🇵🇰 Lahore, Punjab, Pakistan